Trial Profile
Phase II Trial to Assess the Safety and Acceptability of the Long-acting Injectable HIV Integrase Inhibitor, Cabotegravir (GSK1265744), in HIV Uninfected Women in KwaZulu-Natal, South Africa
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2015
Price :
$35
*
At a glance
- Drugs Cabotegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 04 Nov 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 09 Jun 2015 New trial record